Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Comment by AndrewKenon Apr 07, 2020 7:22am
133 Views
Post# 30885697

RE:RE:RE:RE:Boom

RE:RE:RE:RE:Boom

We are thrilled to invest in Lattice as they embark upon Phase I trials of AmnioBoost,” said Adi Nahmani, Managing Member of Alumina Partners. “As medical science struggles to identify safe and effective treatment candidates for COVID-19, every avenue must be explored with all due haste. AmnioBoost is ready for clinical trials, and we look forward to seeing a fully capitalized Lattice move that ball forward
Link: https://www.aluminapartners.com/ -> Team 

 

ADI NAHMANI

Principal & Managing Member

Adi is the founder and Managing Member of Alumina Partners, serving as our Chief Investment Officer and chairing the firm’s investment committee. He first became active with development stage private companies shortly after Y2K and spent several years working with a number of startups. In 2007 he began working with small-cap and emerging growth public companies, helping them to better identify and monetize market opportunities. Further honing an already sharp eye for valuation, Adi founded Alumina to prove that speculative finance need not be a zero-sum game between issuer and investor. In the emerging growth arena, where competition is over rapidly evolving and expanding pies, there should be enough room for the issuer, the institutional investor, and the retail shareholder to succeed together.


 

<< Previous
Bullboard Posts
Next >>